Akebia Therapeutics(AKBA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKBA Akebia Therapeutics

Pre-Mkt 02-09 06:31:26 EST

1.39

+0.01

+0.72%

盘前1.36

-0.03-2.16%

05:34 EST

High1.40	Low1.33	Vol3.42M
Open1.36	D1 Closing1.38	Amplitude5.07%
Mkt Cap368.86M	Tradable Cap361.12M	Total Shares265.37M
T/O4.70M	T/O Rate1.32%	Tradable Shares259.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AKBA","market":"US","secType":"STK","nameCN":"Akebia Therapeutics","latestPrice":1.39,"timestamp":1770411600000,"preClose":1.38,"halted":0,"volume":3420972,"hourTrading":{"tag":"盘前","latestPrice":1.36,"preClose":1.39,"latestTime":"05:34 EST","volume":1709,"amount":2324.2400000000002,"timestamp":1770633256969,"change":-0.03,"changeRate":-0.021583,"amplitude":0},"delay":0,"changeRate":0.00724637681159421,"floatShares":259801013,"shares":265365993,"eps":-0.08,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"02-09 06:31:26 EST","open":1.36,"high":1.4,"low":1.3301,"amount":4697080.7644944005,"amplitude":0.050652,"askPrice":1.48,"askSize":440,"bidPrice":1.24,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.08,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770647400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1395288000000,"exchange":"NASDAQ","adjPreClose":1.39,"preHourTrading":{"tag":"盘前","latestPrice":1.36,"preClose":1.39,"latestTime":"05:34 EST","volume":1709,"amount":2324.2400000000002,"timestamp":1770633256969,"change":-0.03,"changeRate":-0.021583,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.39,"latestTime":"19:59 EST","volume":42552,"amount":58566.965,"timestamp":1770425993271,"change":-0.02,"changeRate":-0.014388,"amplitude":0.014388},"volumeRatio":1.158804382371728,"impliedVol":4.4094,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/AKBA","defaultTab":"news","newsList":[{"id":"2609058597","title":"Akebia Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2609058597","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609058597?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:59","pubTimestamp":1770393540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKBA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2026 10:59 ET (15:59 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA"],"gpt_icon":0},{"id":"2609627593","title":"Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2609627593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609627593?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:34","pubTimestamp":1770381240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKBA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2026 07:34 ET (12:34 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA"],"gpt_icon":0},{"id":"2609560442","title":"Akebia price target lowered to $4 from $6 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2609560442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609560442?lang=en_us&edition=fundamental","pubTime":"2026-02-06 19:56","pubTimestamp":1770378985,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia (AKBA) to $4 from $6 and keeps an Overweight rating on the shares. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/akebia-price-target-lowered-to-4-from-6-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/akebia-price-target-lowered-to-4-from-6-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKBA","BK4139"],"gpt_icon":0},{"id":"2608383500","title":"Akebia Therapeutics Files Initial Beneficial Ownership Statement for Carolyn M. Rucci, SVP and Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608383500","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608383500?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:33","pubTimestamp":1770154407,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Carolyn M. Rucci, who serves as SVP, Chief Legal Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL4gF7s0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Akebia Therapeutics Files Initial Beneficial Ownership Statement for Carolyn M. Rucci, SVP and Chief Legal Officer","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139"],"gpt_icon":0},{"id":"2608890491","title":"BRIEF-Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2608890491","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608890491?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:17","pubTimestamp":1770067061,"startTime":"0","endTime":"0","summary":"BRIEF-Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule Feb 2 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA49THSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2608189001","title":"Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608189001","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608189001?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:05","pubTimestamp":1770066300,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb.  02, 2026  (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/02/3230600/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139"],"gpt_icon":0},{"id":"2607046724","title":"Akebia Therapeutics Updates Executive Severance and Leadership Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2607046724","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607046724?lang=en_us&edition=fundamental","pubTime":"2026-01-30 21:59","pubTimestamp":1769781588,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics ( ($AKBA) ) has provided an announcement. On January 27, 2026, Akebia Therapeutics signed a new 84‑month lease for approximatel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/akebia-therapeutics-updates-executive-severance-and-leadership-terms?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/akebia-therapeutics-updates-executive-severance-and-leadership-terms?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2602487835","title":"Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2602487835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602487835?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:37","pubTimestamp":1768225066,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Akebia Therapeutics ( ($AKBA) ). On January 12, 2026, Akebia Therapeutics announced corporate updates and a 202...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/akebia-therapeutics-outlines-2026-vafseo-strategy-and-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/akebia-therapeutics-outlines-2026-vafseo-strategy-and-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2602551032","title":"BRIEF-Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602551032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602551032?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:03","pubTimestamp":1768223039,"startTime":"0","endTime":"0","summary":"BRIEF-Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027Jan 12 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139"],"gpt_icon":0},{"id":"2602510546","title":"Akebia Therapeutics Reports Strong Vafseo Growth and Advances Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510546","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510546?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222870,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. announced key corporate updates and its 2026 pipeline outlook. The company reported it is positioned to increase the depth of Vafseo  prescribing entering 2026, with access to approximately 275,000 patients. Akebia expects revenue growth to resume in the first quarter of 2026, driven by increased patient access and anticipated improvements in adherence and compliance. In its rare kidney disease pipeline, Akebia dosed the first patient in a Phase 2 clinical trial of Praliciguat for focal segmental glomerulosclerosis  in December 2025 and plans to evaluate the drug in other rare podocytopathies. The company also plans to initiate an open-label Phase 2 rare kidney disease basket trial in the second half of 2026, assessing indications such as IgA Nephropathy , Lupus Nephritis , and C3 Glomerulopathy , with initial data expected in 2027. Additionally, AKB-9090, a HIF-PH inhibitor, is scheduled to enter Phase 1 trials for acute kidney injury associated with cardiac s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3wYbNV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","AKBA","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","SG9999014005.SGD","BK4585","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2601813803","title":"Akebia Therapeutics Doses First Patient in Mid-Stage Study of Kidney Disease Drug Praliciguat","url":"https://stock-news.laohu8.com/highlight/detail?id=2601813803","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601813803?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:16","pubTimestamp":1767709009,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics  said Tuesday it has dosed the first patient in a phase 2 trial of its experimental drug, praliciguat, for the treatment of a rare kidney disease.The company said the study will assess the safety and efficacy of the drug in about 60 adults with the condition who are already being treated with standard treatment.Akebia said the primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio, a key marker of kidney damage. A key secondary endpoint is the percentage of patients achieving partial remission, the company added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKBA","SSI","BK4139"],"gpt_icon":0},{"id":"2601818114","title":"BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat","url":"https://stock-news.laohu8.com/highlight/detail?id=2601818114","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601818114?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:03","pubTimestamp":1767708212,"startTime":"0","endTime":"0","summary":"BRIEF-Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat Jan 6 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2F1STP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA"],"gpt_icon":0},{"id":"2601897502","title":"Akebia Therapeutics Doses First Patient in Phase 2 Trial of Praliciguat for FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897502?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704435,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. has announced the dosing of the first patient in a Phase 2 clinical trial evaluating praliciguat, an oral, once-daily soluble guanylate cyclase  stimulator, for the treatment of biopsy-confirmed focal segmental glomerulosclerosis , a rare kidney disease. The randomized, double-blind, placebo-controlled, multicenter study will enroll approximately 60 adults with FSGS who are already receiving maximally tolerated doses of an ACE inhibitor or angiotensin receptor blocker. The trial’s primary endpoint is the change from baseline in urine protein-to-creatinine ratio  at Week 24. A secondary endpoint will assess the percentage of patients achieving partial remission at Week 24. All participants will receive praliciguat during an additional 24-week open-label extension period. Study results have not yet been presented and will be provided in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL6Xm0wt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","LU2210149790.SGD","LU2095319765.USD","BK4139","BK4588","LU2210150020.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","SG9999014039.USD","LU0314104364.USD","IE00B64PRP62.GBP","AKBA","IE00BGHQF748.EUR","NDAQ"],"gpt_icon":0},{"id":"2601897000","title":"Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897000","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897000?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:00","pubTimestamp":1767704400,"startTime":"0","endTime":"0","summary":"Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction of kidney failureCAMBRIDGE, Mass., Jan.  06, 2026  (GLOBE NEWSWIRE) -- Akebi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213549/37519/en/Akebia-Therapeutics-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Praliciguat-for-the-Treatment-of-Focal-Segmental-Glomerulosclerosis-FSGS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKBA","ARB","FSGS"],"gpt_icon":0},{"id":"2601837895","title":"Akebia Therapeutics Grants Stock Options to New Employee at $1.61 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837895?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647143,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. has granted stock options to a newly hired employee, allowing the purchase of 197,900 shares of common stock at an exercise price of $1.61 per share, reflecting the closing price on the grant date of December 31, 2025. The options vest over four years, with 25% vesting after the first year and the remaining 75% vesting quarterly. Each option carries a 10-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL6XLl18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","AKBA","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","SG9999014021.USD","SG9999014005.SGD","BK4585","SG9999014039.USD","BK4139","LU2210150020.SGD"],"gpt_icon":0},{"id":"2601837937","title":"Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837937","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837937?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647100,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan.  05, 2026  (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3213185/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139"],"gpt_icon":0},{"id":"2588058336","title":"Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058336?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:21","pubTimestamp":1764678060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKBA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2025 07:21 ET (12:21 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA"],"gpt_icon":0},{"id":"2588080467","title":"Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588080467","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588080467?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:05","pubTimestamp":1764623100,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Dec.  01, 2025  (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3197426/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKBA","BK4139"],"gpt_icon":0},{"id":"2588377769","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588377769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588377769?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:32","pubTimestamp":1764613968,"startTime":"0","endTime":"0","summary":"Q32 Bio's  shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio  said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio  said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKBA","BK4007","BLTE","KALA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588577926","title":"Why Is Small-Cap Q32 Bio Stock Soaring On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588577926","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588577926?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:43","pubTimestamp":1764600180,"startTime":"0","endTime":"0","summary":"Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Medical-Business-Handshake.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Medical-Business-Handshake.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49136089/why-is-small-cap-q32-bio-stock-soaring-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49136089/why-is-small-cap-q32-bio-stock-soaring-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["AKBA","BK4139","QTTB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akebia.com","stockEarnings":[{"period":"1week","weight":-0.0142},{"period":"1month","weight":-0.0915},{"period":"3month","weight":-0.3186},{"period":"6month","weight":-0.5936},{"period":"1year","weight":-0.3565},{"period":"ytd","weight":-0.1366}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.00708},{"month":2,"riseRate":0.416667,"avgChangeRate":0.054749},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.075459},{"month":4,"riseRate":0.5,"avgChangeRate":0.022435},{"month":5,"riseRate":0.583333,"avgChangeRate":0.042467},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055123},{"month":7,"riseRate":0.5,"avgChangeRate":0.0412},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.035082},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.057186},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.11772},{"month":11,"riseRate":0.666667,"avgChangeRate":0.130076},{"month":12,"riseRate":0.5,"avgChangeRate":0.078804}],"exchange":"NASDAQ","name":"Akebia Therapeutics","nameEN":"Akebia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akebia Therapeutics(AKBA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Akebia Therapeutics(AKBA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Akebia Therapeutics,AKBA,Akebia Therapeutics股票,Akebia Therapeutics股票老虎,Akebia Therapeutics股票老虎国际,Akebia Therapeutics行情,Akebia Therapeutics股票行情,Akebia Therapeutics股价,Akebia Therapeutics股市,Akebia Therapeutics股票价格,Akebia Therapeutics股票交易,Akebia Therapeutics股票购买,Akebia Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akebia Therapeutics(AKBA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Akebia Therapeutics(AKBA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}